期刊
BIOORGANIC & MEDICINAL CHEMISTRY
卷 14, 期 1, 页码 62-66出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2005.07.053
关键词
aldehyde oxidase; zebularine; raloxifene; 5-benzylacyclouridine; hepatic metabolism inhibition
资金
- NATIONAL CANCER INSTITUTE [Z01BC010642] Funding Source: NIH RePORTER
To aid in the clinical evaluation of zebillarine, a potential oral antitumor agent, we initiated Studies on the metabolism of zebularine in liver cytosol from humans and other mammals. Metabolism by aldehyde oxidase (AO, EC 1.2.3.1) was the major catabolic route, Yielding Uridine as the primary metabolite, which was metabolized further to Uracil by Uridine phosphorylase. The inhibition of zebularine metabolism was Studied using raloxifene, a known potent inhibitor of AO, and 5-benzylacyclouridine (BAU), a previously undescribed inhibitor of AO. The Michaelis-Menten kinetics of aldehyde oxidase and its inhibition by raloxifene and BAU were highly variable between species. (c) 2005 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据